Advanced lymphocyte-rich classical hodgkin lymphoma complicated with fatal hemophagocytic syndrome

Satoshi Ichikawa, Taro Takahashi, Hiroki Katsushima, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Lymphocyte-rich classical Hodgkin lymphoma (LRCHL) is a rare subtype of Hodgkin lymphoma with a favorable prognosis, and an aggressive clinical course of LRCHL is uncommon. A 55-year-old man suffering from swelling in the left neck was diagnosed with LRCHL with extranodal lesions in the lung and bone marrow. Initially, he received standard ABVD chemotherapy; however, disease progression, accompanied by hemophagocytic syndrome (HPS), occurred during the second course of ABVD. He received two subsequent courses of intensive chemotherapy containing high-dose steroids, cyclophosphamide, and etoposide. Nevertheless, this therapy was only temporarily effective, and he died of due to an aggressive disease progression accompanied by uncontrollable HPS and severe coagulopathy.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalInternal Medicine
Issue number2
Publication statusPublished - 2016 Jan 15


  • Hemophagocytic syndrome
  • Lymphocyte-rich classical Hodgkin lymphoma
  • Pulmonary Hodgkin lymphoma


Dive into the research topics of 'Advanced lymphocyte-rich classical hodgkin lymphoma complicated with fatal hemophagocytic syndrome'. Together they form a unique fingerprint.

Cite this